EN CN
Novlead

Led by Science
Driven by Dedication

Novlead Biotech was founded in 2018, focusing on the research and development of novel medical devices. The founders have many years of research, project management and marketing experiences . Novlead builds its own proprietary technologies to generate and control NO. The difficulty in producing and controlling nitric oxide gas has limited the medical applications of NO, though it has been more than 20 years since NO’s physiological effects were discovered. Novlead has overcome this challenge after years of research and partnership with Professor Mark Meyerhoff Lab at Michigan University. Novlead aims to add to the treatment option of existing diseases such as Persistent pulmonary hypertension of the newborn (PPHN), pulmonary fibrosis (PF), as well as pioneering the use of NO in other medical and commercial applications.

Our vision

Novlead Biotech is committed to provide the world's leading medical innovation technology and customized solutions. Our goal is to contribute to a safer and healthier human well-being through our technological innovations.

Our mission

We strive to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.

We strive to exceed customer expectations in terms of safety, efficacy, and value by focusing on the science, development, and commercialization of our innovations.

We strive to enhance materials into outstanding products to improve the quality of life.